Venatorx pharmaceuticals, INC.

Ended Definitive Contract Awarded Last action

Contract number
75A50119C00007
Awardee
Awarding agency
Obligated
$106,573,640

Award facts

Opportunity
Contract value 73% obligated
  • $131,756,813.69 Current, with exercised options
  • $146,866,137.69 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Downingtown, PA 19335, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00030 · The purpose of this bilateral modification DE-obligates canceling year funds from requisition OS256610 in the amount of (-$615,177.10) from CLIN0006 and from… -$615,399
Other Administrative Action P00029 · The purpose of this bilateral modification DE-obligates funds from requisition OS237567 in the amount of (-.01) from CLIN0001. -$0
Other Administrative Action P00028 · The purpose of this modification is to update articles i.1 federal acquisition regulation (far) (48 CFR chapter 1) clauses, 52.204-14 services contract… $0
Other Administrative Action P00027 · The purpose of this modification is to extend CLIN002 period of performance from 3/31/24 to 6/30/2025 and to update/add key personnel per section g.3 key… $0
Funding Only Action P00026 · The purpose of this modification is to provide supplemental funding for CLIN0009, update section g.1 contracting officer, and update attachment 1, statement… $7,000,000
Other Administrative Action P00025 $0
Other Administrative Action P00024 · The purpose of this modification is to extend the period of performance for CLIN0009 from march 31, 2024, to september 30, 2025, at no additional cost to the… $0
Other Administrative Action P00023 · The purpose of this modification is to update provisional billing rates under article g.6 indirect cost rate $0
Other Administrative Action P00022 · The purpose of this modification is to correct the period of performance for CLIN0007 to align with IPP. $0
Other Administrative Action P00021 · The purpose of this modification is to extend the period of performance for CLIN0007 through september 30, 2024, to complete the manufacture and release of… $0
Other Administrative Action P00020 · Administrative modification $0
Other Administrative Action P00019 · The purpose of this modification is to extend the period of performance for CLIN0009 from september 30, 2023, to march 31, 2024 $0
Other Administrative Action P00018 · The purpose of this modification is to provide supplemental funding for CLIN0002, and CLIN0003, extend the period of performance for CLIN0002 through march… $8,368,140
Other Administrative Action P00017 $0
Other Administrative Action P00016 · The purpose of this modification is to update the period of performance for clin 0003 through 9/30/2025. $0
Other Administrative Action P00015 · The purpose of this modification is to update section f deliveries and performance and section g contract administration data: $0
Other Administrative Action P00014 · Update key personnel and provide nces for clins 0001, 0002, and 0003 $0
Funding Only Action P00013 · Add additional funding to clin 0007, update period of performance, and add IPP language $5,000,000
Exercise an Option P00012 · Exercise option 8 clin 0009 and revise govt cost share amount $9,475,856
Other Administrative Action P00011 · NCE on clin 0002 through 3/31/23 and CO change $0
Other Administrative Action P00010 · NCE on clin 0001 through 12/31/2022 and incorporate by executive order 14042 - far deviation clause 52.223-99 $0
Exercise an Option P00009 · Exercise CLIN0003, update b.3. And g.6. $15,707,318
Funding Only Action P00008 · Incorporate assignment of claims per contractor's request, NCE for CLIN0006, and add CS $0
Other Administrative Action P00007 · Providing supplemental funding to CLIN0001; reallocating negotiated amount from CLIN0010/option 9 to CLIN0001; key personnel change; update SOW. $6,279,470
Other Administrative Action P00006 $0
Other Administrative Action P00005 · This product is being developed for the treatment of the following indications: complicated urinary tract infections (cutis), $0
Other Administrative Action P00004 · MOD P00004 is to change contracting officer's representative from tina guina, PH.d. To sheila miknyoczki, PH.d. In all applicable areas of the contract. $0
Exercise an Option P00003 · MOD P00003 is to exercise clin 0002 (option 1) and clin 0006 (option 5) respectively for phase 3 habp/vabp - start up and CMC drug product FSS (REG batched).… $23,313,621
Exercise an Option P00002 · MOD P00002 is to exercise clin 0005 (option 4) and clin 0007 (option 6) respectively for CMC drug substance FSS and CMC drug substance process validation… $11,308,120
Modification $20,736,514
Supplemental Agreement for work within scope P00001 · MOD P00001 is to revise and replace contract milestones and deliverable table in section b.2 base period and b.3.1 cost reimbursement options. $0
Show all 31

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Venatorx Pharmaceuticals Inc. for advanced research and development of medical countermeasures against chemical, biological, radiological, and nuclear threats, with a ceiling value of $146.9 million and an award date of July 17, 2019. The contract operates under cost-sharing pricing with no set-aside.

Place of performance is Downingtown, PA. The originating Broad Agency Announcement from the Biomedical Advanced Research and Development Authority solicited proposals for vaccines, therapeutics, diagnostics, and related countermeasures to advance candidates toward FDA approval or licensure. The ultimate completion date is September 30, 2025.

Government-invoiced labor through FY2024 reflects 14.6 FTEs across 30,302 contractor hours at a blended derived rate of $230.75 per hour, with 2 subcontractors handling approximately 20 percent of contractor hours. FY2024 represents a significant decline from FY2023's 11.0 FTEs and $691.82 hourly rate, consistent with a multi-year downward trend in both labor footprint and pricing across the contract's reported history. FY2021 and FY2022 generated $25.2 million and $18.4 million in invoiced amounts respectively; FY2023 rebounded to $15.8 million before declining to $7 million in FY2024.

Quick answers

Who was awarded contract 75A50119C00007?

75A50119C00007 was awarded to Venatorx Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 17, 2019.

How much is contract 75A50119C00007 worth?

The government has obligated $106,573,640 on 75A50119C00007. Its current value, with exercised options, is $131,756,814. Its potential value, with all options, is $146,866,138.

Was contract 75A50119C00007 competed?

The extent of competition for 75A50119C00007 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login